For most people, high cholesterol is managed with a statin and some lifestyle changes. But a significant minority of patients — those with genetic cholesterol disorders, established heart disease, or an inability to tolerate statins — need something more powerful. Evolocumab, a PCSK9 inhibitor sold under the brand name Repatha, is one of the newer options that can dramatically lower LDL (“bad”) cholesterol when statins alone aren’t enough.
This guide explains what evolocumab is, how it works, how it compares to inclisiran (the other PCSK9-targeted therapy available in Singapore), who it’s for, what it costs, and what to discuss with your doctor. Evolocumab is a prescription-only medication that requires medical supervision — this article is educational and not a substitute for professional advice.
Table of Contents
- What Is Evolocumab?
- Understanding PCSK9 and Cholesterol
- How Evolocumab Works
- Evolocumab vs Inclisiran
- Who Is Evolocumab For?
- How Effective Is It?
- Side Effects & Safety
- Cost in Singapore
- Frequently Asked Questions
💡 KEY INSIGHT
Evolocumab isn’t a replacement for statins — it’s a powerful add-on. For people whose LDL stays high despite maximum statin doses, or who can’t tolerate statins at all, evolocumab can cut LDL cholesterol by a further 50–60%. That’s a level of reduction oral medications rarely achieve, which is why it’s reserved for higher-risk patients rather than used as a first-line treatment.
What Is Evolocumab?
Evolocumab is a monoclonal antibody — a lab-engineered protein — designed to lower LDL cholesterol by blocking a specific protein in the body called PCSK9. It belongs to a class of drugs known as PCSK9 inhibitors, and in Singapore it’s most commonly known by its brand name, Repatha.
Unlike statins, which are taken as daily tablets, evolocumab is given as a subcutaneous injection (under the skin, similar to an insulin injection) every two weeks or once a month. It was developed for people whose cholesterol is difficult to control with conventional oral medications, and it has become an important tool for reducing cardiovascular risk in high-risk patients.
Understanding PCSK9 and Cholesterol
To understand how evolocumab works, it helps to understand PCSK9. PCSK9 (proprotein convertase subtilisin/kexin type 9) is a protein made mainly by the liver. Its job is to regulate how much LDL cholesterol your body removes from the blood.
Here’s the chain of events: your liver has LDL receptors on its surface that grab LDL cholesterol from the bloodstream and clear it. PCSK9 binds to these receptors and causes them to be broken down. The more PCSK9 you have, the fewer LDL receptors survive — and the less LDL your liver can clear. The result is higher LDL cholesterol circulating in your blood.
In other words, PCSK9 acts like a brake on your body’s ability to clear “bad” cholesterol. Block that brake, and the liver clears far more LDL.
How Evolocumab Works
Evolocumab works by binding directly to PCSK9 in the bloodstream and neutralising it. With PCSK9 out of action, more LDL receptors survive on the liver’s surface, and those receptors clear more LDL cholesterol from the blood. The effect of each dose lasts roughly two to four weeks, which is why evolocumab is injected every two weeks or monthly.
Because evolocumab targets a completely different pathway from statins, the two work well together. Statins reduce how much cholesterol the liver produces; evolocumab increases how much the liver clears. Combined, they can drive LDL far lower than either could alone.
Evolocumab vs Inclisiran
Singapore has two PCSK9-targeted therapies: evolocumab and inclisiran (brand name Leqvio). Both lower PCSK9, but they do it in fundamentally different ways.
Evolocumab (Repatha)
Evolocumab is a monoclonal antibody that binds and inactivates PCSK9 already circulating in the blood. It’s injected every two weeks (140 mg) or monthly (420 mg), and patients can be trained to self-inject at home using a pre-filled pen or auto-injector.
Inclisiran (Leqvio)
Inclisiran uses a newer technology called small interfering RNA (siRNA), which silences the genetic instructions for making PCSK9 in the first place. Because it reduces production rather than mopping up existing protein, its effect lasts much longer — it’s given as an initial dose, a second dose at three months, then just once every six months, usually in a clinic.
| Feature | Evolocumab | Inclisiran |
|---|---|---|
| Drug class | Monoclonal antibody | Small interfering RNA (siRNA) |
| Mechanism | Blocks PCSK9 in blood | Reduces PCSK9 production in liver |
| Administration | Subcutaneous injection | Subcutaneous injection |
| Frequency | Every 2 weeks or monthly | Start, 3 months, then every 6 months |
| LDL reduction | ~50–60% (added to statin) | ~50% (added to statin) |
| Outcome data | Established (FOURIER trial) | Outcome trials ongoing |
The right choice depends on individual cardiovascular risk, how comfortable you are self-injecting, dosing convenience, and clinical guidelines. One practical difference: evolocumab has longer-established cardiovascular outcome data (from the FOURIER trial), while inclisiran’s convenience — two injections a year after the first year — appeals to patients who prefer fewer clinic visits.
Who Is Evolocumab For?
Evolocumab is not a first-line treatment. It’s typically considered for people who fall into one or more of these groups:
- Established cardiovascular disease — those who’ve had a heart attack or stroke, or have known coronary disease, and whose LDL stays high despite maximum statin therapy
- Familial hypercholesterolaemia — a genetic condition causing very high LDL from a young age
- Statin intolerance — people who can’t take statins due to muscle pain, liver effects, or other documented side effects
- Very high cardiovascular risk — patients who need aggressive LDL reduction to lower their risk of future events
In each case, a doctor assesses overall cardiovascular risk and confirms that statins and other oral therapies have been optimised first before adding evolocumab.
How Effective Is Evolocumab?
In clinical trials, evolocumab reduced LDL cholesterol by approximately 50–60% on top of what statins achieved alone. These reductions are sustained with continued treatment, and many patients reach LDL levels below current optimal targets.
To put that in context: a patient on a statin with an LDL of 3.5 mmol/L might see it fall to roughly 1.5–1.8 mmol/L after adding evolocumab. For high-risk patients — those with established cardiovascular disease or familial hypercholesterolaemia — that degree of reduction can meaningfully lower the risk of future heart attacks and strokes. The FOURIER trial specifically demonstrated a reduction in cardiovascular events with evolocumab.
Side Effects & Safety
Evolocumab is generally well tolerated. The most common side effects are mild:
- Injection site reactions (redness, mild pain, bruising)
- Muscle aches
- Mild upper respiratory symptoms
Less commonly, some people experience allergic reactions, headache, or fatigue. Serious side effects are uncommon, and unlike statins, evolocumab is not typically associated with significant muscle or liver problems — which is part of why it’s an option for statin-intolerant patients. As with any relatively new medication, long-term safety data continues to accumulate.
Cost of Evolocumab in Singapore
Evolocumab is significantly more expensive than statins, which are inexpensive generic medications. The actual cost depends on several factors: the specific dosing schedule, whether you’re treated in a public hospital, polyclinic, or private clinic, and your insurance coverage.
Coverage under MediShield Life, integrated shield plans, and whether the medication appears on the Standard Drug List or is eligible for the Medication Assistance Fund all affect out-of-pocket cost. Because pricing varies so much between settings and schemes, the most reliable figures come from your doctor or clinic pharmacist based on your specific situation. It’s a genuine consideration, since evolocumab is usually continued long-term.
Where to Get Assessed in Singapore
Because evolocumab is prescription-only and reserved for specific patient groups, the first step is a proper cholesterol and cardiovascular risk assessment. This can be done by a GP experienced in lipid management, often co-managed with a cardiologist or lipidologist for complex cases.
Nee Soon Clinic in Yishun is one Singapore clinic that manages high cholesterol and discusses PCSK9 inhibitor options such as evolocumab and inclisiran as part of cardiovascular risk management. Their detailed doctor’s guide comparing the two therapies is a useful further read: PCSK9 Inhibitors Explained: Evolocumab vs Inclisiran. Whichever clinic you choose, the key is a doctor who will optimise first-line therapies, assess your risk properly, and monitor treatment over time.
Conclusion
Evolocumab represents a meaningful advance in managing difficult-to-treat high cholesterol. For people with established heart disease, familial hypercholesterolaemia, or statin intolerance, it offers LDL reductions that oral medications rarely match. It’s not a substitute for a healthy diet, exercise, or first-line therapies — but as an add-on for higher-risk patients, it can make a real difference to long-term cardiovascular health. The right approach is always personalised, decided with a doctor who understands your full risk picture.
Related Reading
- Mounjaro Singapore: 2026 Price Guide
- Wegovy Singapore: Why Semaglutide Works for Some But Not Others
Frequently Asked Questions
1. Is evolocumab a replacement for statins?
No. Evolocumab is usually added to statin therapy rather than replacing it, because the two work through different mechanisms and complement each other. The exception is people who genuinely can’t tolerate statins, where evolocumab may be used as an alternative under medical supervision.
2. How quickly does evolocumab lower cholesterol?
LDL reductions are typically seen within two to four weeks of starting treatment, and the effect is sustained as long as treatment continues.
3. Can I self-inject evolocumab at home?
Yes. After appropriate training, most patients can self-inject evolocumab at home using a pre-filled pen or auto-injector, every two weeks or monthly. Inclisiran, by contrast, is usually given in a clinic.
4. Can I stop evolocumab once my cholesterol is controlled?
Generally no. LDL levels rise again within weeks to months of stopping, so evolocumab is usually continued long-term to maintain the benefit. Any changes should be made with your doctor.
5. Are the injections painful?
Most patients describe the injections as mildly uncomfortable but tolerable. Injection-site reactions, when they occur, are usually minor — some redness, mild pain, or bruising that resolves quickly.
6. Is evolocumab safe in pregnancy?
Evolocumab is not recommended during pregnancy. If you are pregnant, planning a pregnancy, or breastfeeding, discuss this with your doctor before starting, as cholesterol treatment plans are usually adjusted during this time.
A Note from Gaia Guides
Evolocumab is a prescription medication for a specific problem: high cardiovascular risk with cholesterol that won’t come down by other means. It isn’t a lifestyle shortcut, and it isn’t for everyone with high cholesterol — most people are well served by statins, diet, and exercise. If your LDL stays stubbornly high despite doing the right things, though, it’s worth asking your doctor whether a PCSK9 inhibitor like evolocumab fits your risk profile. This article is educational only and not medical advice; treatment decisions should always be made with a qualified doctor.
Experts You Can Trust
✓ Evidence-Based & Fact-Checked. Last updated May 2026.
This article draws on published cardiovascular research, clinical trial data (including the FOURIER trial), and guidance from Singapore lipid-management practitioners. It is educational and not a substitute for personalised medical advice from a qualified doctor.
Sources & References:
- Nee Soon Clinic — PCSK9 Inhibitors: Evolocumab vs Inclisiran: neesoonclinic.sg
- Repatha (evolocumab) official information: https://www.repatha.com/
- National Center for Biotechnology Information — PCSK9 inhibitor research: https://www.ncbi.nlm.nih.gov/pubmed/
- Health Sciences Authority Singapore — Medicines: https://www.hsa.gov.sg/
- Ministry of Health Singapore — Chronic disease management: https://www.moh.gov.sg/
Tags: evolocumab, evolocumab Singapore, Repatha, PCSK9 inhibitors, high cholesterol Singapore, inclisiran, LDL cholesterol